, CA (PressExposure) June 05, 2009 -- Given the high drug attrition rates and the declining number of new chemical entities turned into approved medicines, there exists an urgent need to increase the effectiveness and probability of success of the classical drug discovery process. An alarming statistics in drug development indicate that the average success rate for all therapeutic areas is approximately 11% and only 1 in 9 compounds makes it through development to get approved by the regulatory agencies. There exists an urgent need to increase the effectiveness and probability of success of the pharmaceutical industry by integrating biomarkers in early development. Translational medicine became an essential component of this effort and is one of the largest growing areas of drug discovery and development.
For these reasons the field of Translational Medicine is of continuously escalating significance. The Translational Medicine Track of the GTCbio 5th Annual Modern Drug Discovery & Development Conference will be held October 14-16, 2009 in San Diego, CA. The conference covers a wide range of topics in the field, from the new technologies facilitating biomarker discovery and the identification of safety biomarkers used to measure toxicity in vital organs, to the development of more predictive pre-clinical models and the discussion of partnering opportunities in translational medicine. This conference offers scientists, clinicians, medical practitioners and specialists, students, R&D experts and patients the opportunity to meet and discuss the latest breakthroughs and advances in the field of biomarkers and translational medicine.